Skip to main content
NCBI home page
The AAPS Journal logoLink to The AAPS Journal
. 2005 Oct 27;7(3):E739–E751. doi: 10.1208/aapsj070374

Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters

Christopher K Surratt 1,✉, Okechukwu T Ukairo 1, Suneetha Ramanujapuram 1
PMCID: PMC2751276  PMID: 16353950

Abstract

The plasma membrane monoamine transporters terminate neurotransmission by removing dopamine, norepinephrine, or serotonin from the synaptic cleft between neurons. Specific inhibitors for these transporters, including the abused psychostimulants cocaine and amphetamine and the tricyclic and SSRI classes of antidepressants, exert their physiological effects by interfering with synaptic uptake and thus prolonging the actions of the monoamine. Pharmacological, biochemical, and immunological characterization of the many site-directed, chimeric, and deletion mutants generated for the plasma membrane monoamine transporters have revealed much about the commonalities and dissimilarities between transporter substrate, ion, and inhibitor binding sites. Mutations that alter the binding affinity or substrate uptake inhibition potency of inhibitors by at least 3-fold are the focus of this review. These findings are clarifying the picture regarding substrate uptake inhibitor/transporter protein interactions at the level of the drug pharmacophore and the amino acid residue, information necessary for rational design of novel medications for substance abuse and a variety of psychiatric disorders.

Keywords: transporter, neurotransmitter, antidepressant, addiction, cocaine

Full Text

The Full Text of this article is available as a PDF (393.7 KB).

References

  • 1.Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204:355–360. doi: 10.1016/j.taap.2004.08.013. [DOI] [PubMed] [Google Scholar]
  • 2.Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol. 2003;479:23–40. doi: 10.1016/j.ejphar.2003.08.054. [DOI] [PubMed] [Google Scholar]
  • 3.Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132–2133. doi: 10.1016/S0140-6736(99)04030-1. [DOI] [PubMed] [Google Scholar]
  • 4.Spencer TJ, Biederman J, Madras BK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005;57:1293–1300. doi: 10.1016/j.biopsych.2005.03.036. [DOI] [PubMed] [Google Scholar]
  • 5.Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson’s disease. Neuron. 2003;40:453–456. doi: 10.1016/S0896-6273(03)00684-6. [DOI] [PubMed] [Google Scholar]
  • 6.Sidhu A, Wersinger C, Vernier P. Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson’s disease. FEBS Lett. 2004;565:1–5. doi: 10.1016/j.febslet.2004.03.063. [DOI] [PubMed] [Google Scholar]
  • 7.Dubertret C, Hanoun N, Ades J, Hamon M, Gorwood P. Family-based association study of the 5-HT transporter gene and schizophrenia. Int J Neuropsychopharmacol. 2005;8:87–92. doi: 10.1017/S1461145704004948. [DOI] [PubMed] [Google Scholar]
  • 8.Keikhaee MR, Fadai F, Sargolzaee MR, Javanbakht A, Najmabadi H, Ohadi M. Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2005;135:47–49. doi: 10.1002/ajmg.b.30174. [DOI] [PubMed] [Google Scholar]
  • 9.Wong DF, Harris JC, Naidu S, et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci USA. 1996;93:5539–5543. doi: 10.1073/pnas.93.11.5539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci. 2003;23:4470–4478. doi: 10.1523/JNEUROSCI.23-11-04470.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorders. Psychiatry Res. 2004;132:173–181. doi: 10.1016/j.pscychresns.2003.10.004. [DOI] [PubMed] [Google Scholar]
  • 12.Sutcliffe JS, Delahanty RJ, Prasad HC, et al. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet. 2005;77:265–279. doi: 10.1086/432648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389. doi: 10.1126/science.1083968. [DOI] [PubMed] [Google Scholar]
  • 14.Inoue K, Itoh K, Yoshida K, Shimizu T, Suzuki T. Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a Japanese population. Neuropsychobiology. 2004;50:301–304. doi: 10.1159/000080957. [DOI] [PubMed] [Google Scholar]
  • 15.Saier MH. A functional-phylogenetic system for the classification of transport proteins. J Cell Biochem. 1999;75:84–94. doi: 10.1002/(SICI)1097-4644(1999)75:32+<84::AID-JCB11>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  • 16.Rudnick G. Mechanisms of biogenic amine neurotransmitter transporters. In: Reith MEA, editor. Neurotransmitter Transporters: Structure, Function, and Regulation. Totowa, NJ: Humana Press Inc; 1997. pp. 73–100. [Google Scholar]
  • 17.Goldberg NR, Beuming T, Soyer OS, Goldstein RA, Weinstein H, Javitch JA. Probing conformational changes in neurotransmitter transporters: a structural context. Eur J Pharmacol. 2003;479:3–12. doi: 10.1016/j.ejphar.2003.08.052. [DOI] [PubMed] [Google Scholar]
  • 18.Chen N, Zhen J, Reith ME. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. J Neurochem. 2004;89:853–864. doi: 10.1111/j.1471-4159.2004.02386.x. [DOI] [PubMed] [Google Scholar]
  • 19.Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA. 1992;89:7782–7785. doi: 10.1073/pnas.89.16.7782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, Dixon RAF. Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J Biol Chem. 1988;263:10267–10271. [PubMed] [Google Scholar]
  • 21.Wang W, Sonders MS, Ukairo OT, Scott H, Kloetzel MK, Surratt CK. Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter. Mol Pharmacol. 2003;64:430–439. doi: 10.1124/mol.64.2.430. [DOI] [PubMed] [Google Scholar]
  • 22.Ukairo OT, Bondi CD, Newman AH, et al. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther. 2005;314:575–583. doi: 10.1124/jpet.105.085829. [DOI] [PubMed] [Google Scholar]
  • 23.Barker EL, Moore KR, Rakhshan F, Blakely RD. Transmembrane doamin I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci. 1999;19:4705–4717. doi: 10.1523/JNEUROSCI.19-12-04705.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Carroll FI, Lewin AH, Boja JW, Kuhar MJ. Cocaine receptor: biochemical characterization and structure-activity relationships of cacaine analogues at the dopamine transporter. J Med Chem. 1992;35:969–981. doi: 10.1021/jm00084a001. [DOI] [PubMed] [Google Scholar]
  • 25.Madras BK, Pristupa ZB, Niznik HB, et al. Nitrogen-based drugs are not essential for blockade of monoamine transporters. Synapse. 1996;24:340–348. doi: 10.1002/(SICI)1098-2396(199612)24:4<340::AID-SYN4>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  • 26.Kozikowski AP, Simoni D, Roberti M, et al. Synthesis of 8-oxa analogues of norcocaine endowed with interesting cocaine-like activity. Bioorg Med Chem Lett. 1999;9:1831–1836. doi: 10.1016/S0960-894X(99)00273-5. [DOI] [PubMed] [Google Scholar]
  • 27.Chen N, Vaughan RA, Reigh ME. The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. J Neurochem. 2001;77:1116–1127. doi: 10.1046/j.1471-4159.2001.00312.x. [DOI] [PubMed] [Google Scholar]
  • 28.Zhen J, Maiti S, Chen N, Dutta AK, Reith ME. Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4-fluorobenzyl)piperidine and aspartate 68 in the human dopamine transporter. Eur J Pharmacol. 2004;506:17–26. doi: 10.1016/j.ejphar.2004.10.028. [DOI] [PubMed] [Google Scholar]
  • 29.Lin Z, Wang W, Uhl GR. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains. Mol Pharmacol. 2000;58:1581–1592. doi: 10.1124/mol.58.6.1581. [DOI] [PubMed] [Google Scholar]
  • 30.Reith ME, Berfield JL, Wang LC, Ferrer JV, Javitch JA. The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem. 2001;276:29012–29018. doi: 10.1074/jbc.M011785200. [DOI] [PubMed] [Google Scholar]
  • 31.Adkins EM, Barker EL, Blakely RD. Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol Pharmacol. 2001;59:514–523. doi: 10.1124/mol.59.3.514. [DOI] [PubMed] [Google Scholar]
  • 32.Barker EL, Perlman MA, Adkins EM, et al. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. J Biol Chem. 1998;273:19459–19468. doi: 10.1074/jbc.273.31.19459. [DOI] [PubMed] [Google Scholar]
  • 33.Javitch JA, Shi L, Liapakis G. Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors. Methods Enzymol. 2002;343:137–156. doi: 10.1016/S0076-6879(02)43131-X. [DOI] [PubMed] [Google Scholar]
  • 34.Henry LK, Adkins EM, Han Q, Blakely RD. Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I. J Biol Chem. 2003;278:37052–37063. doi: 10.1074/jbc.M305514200. [DOI] [PubMed] [Google Scholar]
  • 35.Ferrer JV, Javitch JA. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc Natl Acad Sci USA. 1998;95:9238–9243. doi: 10.1073/pnas.95.16.9238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Gaffaney JD, Vaughan RA. Uptake inhibitors but not substrates induce protease resistance in extracellular loop two of the dopamine transporter. Mol Pharmacol. 2004;65:692–701. doi: 10.1124/mol.65.3.692. [DOI] [PubMed] [Google Scholar]
  • 37.Lin Z, Wang W, Kopajtic T, Revay RS, Uhl GR. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol. 1999;56:434–447. doi: 10.1124/mol.56.2.434. [DOI] [PubMed] [Google Scholar]
  • 38.Melamed N, Kanner BI. Transmembrane domains I and II of the gamma-aminobutyric acid transporter GAT-4 contain molecular determinants of substrate specificity. Mol Pharmacol. 2004;65:1452–1461. doi: 10.1124/mol.65.6.1452. [DOI] [PubMed] [Google Scholar]
  • 39.Zhou Y, Bennett ER, Kanner BI. The aqueous accessibility the external half of transmem brane domain I of the GABA transporter GAT-1 is modulated by its ligands. J Biol Chem. 2004;279:13800–13808. doi: 10.1074/jbc.M311579200. [DOI] [PubMed] [Google Scholar]
  • 40.Wu X, Gu HH. Cocaine affinity decreased by mutations of aromatic residue phenylalanine 105 in the transmembrane domain 2 of dopamine transporter. Mol Pharmacol. 2003;63:653–658. doi: 10.1124/mol.63.3.653. [DOI] [PubMed] [Google Scholar]
  • 41.Sato Y, Zhang YW, Androutsellis-Theotokis A, Rudnick G. Analysis of transmembrane domain 2 of rat serotonin transporter by cysteine scanning mutagenesis. J Biol Chem. 2004;279:22926–22933. doi: 10.1074/jbc.M312194200. [DOI] [PubMed] [Google Scholar]
  • 42.Chen R, Han DD, Gu HH. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J Neurochem. 2005;94:352–359. doi: 10.1111/j.1471-4159.2005.03199.x. [DOI] [PubMed] [Google Scholar]
  • 43.Sucic S, Paczkowski FA, Runkel F, Bonisch H, Bryan-Lluka LJ. Functional significance of a highly conserved glutamate residue of the human noradrenaline transporter. J Neurochem. 2002;81:344–354. doi: 10.1046/j.1471-4159.2002.00826.x. [DOI] [PubMed] [Google Scholar]
  • 44.Keshet GI, Bendahan A, Su H, Mager S, Lester HA, Kanner BI. Glutamate-101 is critical for the function of the sodium and chloride-coupled GABA transporter GAT-1. FEBS Lett. 1995;371:39–42. doi: 10.1016/0014-5793(95)00859-8. [DOI] [PubMed] [Google Scholar]
  • 45.Lee SH, Kang SS, Son H, Lee YS. The region of dopamine transporter encompassing the 3rd transmembrane domain is crucial for function. Biochem Biophys Res Commun. 1998;246:347–352. doi: 10.1006/bbrc.1998.8618. [DOI] [PubMed] [Google Scholar]
  • 46.Lee SH, Chang MY, Lee KH, Park BS, Lee YS, Chin HR. Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter. Mol Pharmacol. 2000;57:883–889. [PubMed] [Google Scholar]
  • 47.Lin Z, Uhl GR. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol. 2002;61:885–891. doi: 10.1124/mol.61.4.885. [DOI] [PubMed] [Google Scholar]
  • 48.Chen J-G, Sachpatzidis A, Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J Biol Chem. 1997;272:28321–28327. doi: 10.1074/jbc.272.45.28321. [DOI] [PubMed] [Google Scholar]
  • 49.Chen J-G, Rudnick G. Permeation and gating residues in serotonin transporter. Proc Natl Acad Sci USA. 2000;97:1044–1049. doi: 10.1073/pnas.97.3.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Loland CJ, Granas C, Javitch JA, Gether U. Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. J Biol Chem. 2004;279:3228–3238. doi: 10.1074/jbc.M304755200. [DOI] [PubMed] [Google Scholar]
  • 51.Kristensen AS, Larsen MB, Johnsen LB, Wiborg O. Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants. Eur J Neurosci. 2004;19:1513–1523. doi: 10.1111/j.1460-9568.2004.03202.x. [DOI] [PubMed] [Google Scholar]
  • 52.Mortensen OV, Kristensen AS, Wiborg O. Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J Neurochem. 2001;79:237–247. doi: 10.1046/j.1471-4159.2001.00587.x. [DOI] [PubMed] [Google Scholar]
  • 53.Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem. 2005;92:21–28. doi: 10.1111/j.1471-4159.2004.02835.x. [DOI] [PubMed] [Google Scholar]
  • 54.Paczkowski FA, Bryan-Lluka LJ. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology. Brain Res Mol Brain Res. 2001;97:32–42. doi: 10.1016/S0169-328X(01)00295-9. [DOI] [PubMed] [Google Scholar]
  • 55.Kopajtic T, Rucker C, Seidleck BK, Blaschak CJ, Surratt CK. Glycine substitution of selected dopamine transporter (DAT) proline residues predicted for transmembrane domains: effects on dopamine uptake and affinities for cocaine analogs and other DAT ligands. Soc Neurosci Abs. 1997;23:408–408. [Google Scholar]
  • 56.Lin Z, Itokawa M, Uhl GR. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. FASEB J. 2000;14:715–728. doi: 10.1096/fasebj.14.5.715. [DOI] [PubMed] [Google Scholar]
  • 57.Paczkowski FA, Bryan-Lluka LJ. Role of proline residues in the expression and function of the human noradrenaline transporter. J Neurochem. 2004;88:203–211. doi: 10.1111/j.1471-4159.2004.02149.x. [DOI] [PubMed] [Google Scholar]
  • 58.Williams KA, Deber CM. Proline residues in transmembrane helices: structural or dynamic role? Biochemistry. 1991;30:8919–8923. doi: 10.1021/bi00101a001. [DOI] [PubMed] [Google Scholar]
  • 59.Brandl CJ, Deber CM. Hypothesis about the function of membrane-buried proline residues in transport proteins. Proc Natl Acad Sci USA. 1986;83:917–921. doi: 10.1073/pnas.83.4.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Barlow DJ, Thornton JM. Helix geometry in proteins. J Mol Biol. 1988;201:601–619. doi: 10.1016/0022-2836(88)90641-9. [DOI] [PubMed] [Google Scholar]
  • 61.Li S-C, Goto NK, Williams KA, Deber CM. α-Helical, but not β-sheet, propensity of proline is determined by peptide environment. Proc Natl Acad Sci USA. 1996;93:6676–6681. doi: 10.1073/pnas.93.13.6676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Ri Y, Ballesteros JA, Abrams CK, et al. The role of a conserved proline residue in mediating conformational changes associated with voltage gating of Cx32 gap junctions. Biophys J. 1999;76:2887–2898. doi: 10.1016/S0006-3495(99)77444-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Visiers I, Weinstein H, Rudnick G, Stephan MM. A second site rescue mutation partially restores functional expression to the serotonin transporter mutant V382P. Biochemistry. 2003;42:6784–6793. doi: 10.1021/bi0273415. [DOI] [PubMed] [Google Scholar]
  • 64.Sansom MS, Weinstein H. Hinges, swivels and switches: the role of prolines in signalling via transmembrane alpha-helices. Trends Pharmacol Sci. 2000;21:445–451. doi: 10.1016/S0165-6147(00)01553-4. [DOI] [PubMed] [Google Scholar]
  • 65.Eisenman G, Dani JA. An introduction to molecular architecture and permeability of ion channels. Annu Rev Biophys Biophys Chem. 1987;16:205–226. doi: 10.1146/annurev.bb.16.060187.001225. [DOI] [PubMed] [Google Scholar]
  • 66.Sansom MSP. Proline residues in transmembrane helices of channel and transport proteins: a molecular modelling study. Protein Eng. 1992;5:53–60. doi: 10.1093/protein/5.1.53. [DOI] [PubMed] [Google Scholar]
  • 67.Chen N, Sun L, Reith ME. Cationic interactions at the human dopamine transporter reveal binding conformations for dopamine distinguishable from those for the cocaine analog 2 alpha-carbomethoxy-3 alpha-(4-fluorophenyl)tropane. J Neurochem. 2002;81:1383–1393. doi: 10.1046/j.1471-4159.2002.00941.x. [DOI] [PubMed] [Google Scholar]
  • 68.Chen N, Reith ME. Na+ and the substrate permeation pathway in dopamine transporters. Eur J Pharmacol. 2003;479:213–221. doi: 10.1016/j.ejphar.2003.08.070. [DOI] [PubMed] [Google Scholar]
  • 69.Buck KJ, Amara SG. Structural domains of catecholamine transporter chimeras in involved in selective inhibition by antidepressants and psychomotor stimulants. Mol Pharmacol. 1995;48:1030–1037. [PubMed] [Google Scholar]
  • 70.Giros B, Wang Y, Suter S, Mestikawy SE, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem. 1994;269:15985–15988. [PubMed] [Google Scholar]
  • 71.Roubert C, Cox PJ, Bruss M, Hamon M, Bonisch H, Giros B. Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J Biol Chem. 2001;276:8254–8260. doi: 10.1074/jbc.M009798200. [DOI] [PubMed] [Google Scholar]
  • 72.Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RA. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem. 1989;264:13572–13578. [PubMed] [Google Scholar]
  • 73.Danek Burgess KS, Justice JB. Effects of serine mutations in transmembrane domain 7 of the human an norepinephrine transporter on substrate binding and transport. J Neurochem. 1999;73:656–664. doi: 10.1046/j.1471-4159.1999.0730656.x. [DOI] [PubMed] [Google Scholar]
  • 74.Penado KM, Rudnick G, Stephan MM. Critical amino acid residues in transmembrane span 7 of the serotonin transporter identified by random mutagenesis. J Biol Chem. 1998;273:28098–28106. doi: 10.1074/jbc.273.43.28098. [DOI] [PubMed] [Google Scholar]
  • 75.Kamdar G, Penado KM, Rudnick G, Stephan MM. Functional role of critical stripe residues in transmembrane span 7 of the serotonin transporter: effects of Na+, Li+, and methanethiosulfonate reagents. J Biol Chem. 2001;276:4038–4045. doi: 10.1074/jbc.M008483200. [DOI] [PubMed] [Google Scholar]
  • 76.Itokawa M, Lin Z, Cai NS, et al. Dopamine transporter transmembrane domain polar mutants: ΔG and ΔΔG values implicate regions important for transporter functions. Mol Pharmacol. 2000;57:1093–1103. [PubMed] [Google Scholar]
  • 77.Uhl GR, Lin Z. The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol. 2003;479:71–82. doi: 10.1016/j.ejphar.2003.08.058. [DOI] [PubMed] [Google Scholar]
  • 78.Sur C, Betz H, Schloss P. A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter. Proc Natl Acad Sci USA. 1997;94:7639–7644. doi: 10.1073/pnas.94.14.7639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Barker EL, Kimmel HL, Blakely RD. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol Pharmacol. 1994;46:799–807. [PubMed] [Google Scholar]
  • 80.Barker EL, Blakely RD. Identification of a single amino acid, Phenylalanine 586, that is responsible for high affinity, interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996;50:957–965. [PubMed] [Google Scholar]
  • 81.Smicun Y, Campbell SD, Chen MA, Gu H, Rudnick G. The role of external loop regions in serotonin transport: loop scanning mutagenesis of the serotonin transporter external domain. J Biol Chem. 1999;274:36058–36064. doi: 10.1074/jbc.274.51.36058. [DOI] [PubMed] [Google Scholar]
  • 82.Norgaard-Nielsen K, Norregaard L, Hastrup H, Javitch JA, Gether U. Zn(2+) site engineering at the oligomeric interface of the dopamine transporter. FEBS Lett. 2002;524:87–91. doi: 10.1016/S0014-5793(02)03008-9. [DOI] [PubMed] [Google Scholar]
  • 83.Loland CJ, Norregaard L, Gether U. Defining proximity relationships in the tertiary structure of the dopamine transporter: identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site. J Biol Chem. 1999;274:36928–36934. doi: 10.1074/jbc.274.52.36928. [DOI] [PubMed] [Google Scholar]
  • 84.Fischer JF, Cho AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther. 1979;208:203–209. [PubMed] [Google Scholar]
  • 85.Khoshbouei H, Sen N, Guptaroy B, et al. N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2004;2:E78–E78. doi: 10.1371/journal.pbio.0020078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Granas C, Ferrer J, Loland CJ, Javitch JA, Gether U. N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J Biol Chem. 2003;278:4990–5000. doi: 10.1074/jbc.M205058200. [DOI] [PubMed] [Google Scholar]
  • 87.Seidel S, Singer EA, Just H, et al. Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. Mol Pharmacol. 2005;67:140–151. doi: 10.1124/mol.67.1.. [DOI] [PubMed] [Google Scholar]
  • 88.Sucic S, Bryan-Lluka LJ. The role of the conserved GXXXRXG motif in the expression and function of the human norepinephrine transporter. Brain Res Mol Brain Res. 2002;108:40–50. doi: 10.1016/S0169-328X(02)00512-0. [DOI] [PubMed] [Google Scholar]
  • 89.Loland CJ, Norregaard L, Litman T, Gether U. Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc Natl Acad Sci USA. 2002;99:1683–1688. doi: 10.1073/pnas.032386299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Chen N, Rickey J, Berfield JL, Reith ME. Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding. J Biol Chem. 2004;279:5508–5519. doi: 10.1074/jbc.M306294200. [DOI] [PubMed] [Google Scholar]
  • 91.Lee FJ, Pristupa ZB, Ciliax BJ, Levey AI, Niznik HB. The dopamine transporter carboxyl-terminal tail; truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain. J Biol Chem. 1996;271:20885–20894. doi: 10.1074/jbc.271.34.20885. [DOI] [PubMed] [Google Scholar]
  • 92.Hastrup H, Karlin A, Javitch JA. Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci USA. 2001;98:10055–10060. doi: 10.1073/pnas.181344298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Hastrup H, Sen N, Javitch JA. The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs. J Biol Chem. 2003;278:45045–45048. doi: 10.1074/jbc.C300349200. [DOI] [PubMed] [Google Scholar]
  • 94.Kilic F, Rudnick G. Oligomerization of serotonin transporter and its functional consequences. Proc Natl Acad Sci USA. 2000;97:3106–3111. doi: 10.1073/pnas.060408997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Torres GE, Yao WD, Mohn AR, et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 2001;30:121–134. doi: 10.1016/S0896-6273(01)00267-7. [DOI] [PubMed] [Google Scholar]
  • 96.Lee KH, Kim MY, Kim DH, Lee YS. Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem Res. 2004;29:1405–1409. doi: 10.1023/B:NERE.0000026404.08779.43. [DOI] [PubMed] [Google Scholar]
  • 97.Sung U, Apparsundaram S, Galli A, et al. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci. 2003;23:1697–1709. doi: 10.1523/JNEUROSCI.23-05-01697.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Deken SL, Beckman ML, Boos L, Quick MW. Transport rates of GABA transporters regulation by the N-terminal domain and syntaxin 1A. Nat Neurosci. 2000;3:998–1003. doi: 10.1038/79939. [DOI] [PubMed] [Google Scholar]
  • 99.Pristupa ZB, Wilson JM, Hoffman BJ, Kish SJ, Niznik HB. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994;45:125–135. [PubMed] [Google Scholar]
  • 100.Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther. 1999;289:877–885. [PubMed] [Google Scholar]
  • 101.Williams KA, Geldmacher-Kaufer U, Padan E, Schuldiner S, Kuhlbrandt W. Projection structure of NhaA, a secondary transporter fromEscherichia coli, at 4.0 A resolution. EMBO J. 1999;18:3558–3563. doi: 10.1093/emboj/18.13.3558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Williams KA. Three-dimensional structure of the ion-coupled transport protein NhaA. Nature. 2000;403:112–115. doi: 10.1038/47534. [DOI] [PubMed] [Google Scholar]
  • 103.Ravna AW, Sylte I, Dahl SG. Molecular model of the neural dopamine transporter. J Comput Aided Mol’Des. 2003;17:367–382. doi: 10.1023/A:1026116017725. [DOI] [PubMed] [Google Scholar]
  • 104.Ravna AW, Sylte I, Dahl SG. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters. J Pharmacol Exp Ther. 2003;307:34–41. doi: 10.1124/jpet.103.054593. [DOI] [PubMed] [Google Scholar]
  • 105.Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl− dependent neurotransmitter transporters. Nature. 2005;437:215–223. doi: 10.1038/nature03978. [DOI] [PubMed] [Google Scholar]
  • 106.Lee SH, Chang MY, Jeon DJ, et al. The functional domains of dopamine transporter for cocaine analog, CFT binding. Exp Mol Med. 2002;34:90–94. doi: 10.1038/emm.2002.13. [DOI] [PubMed] [Google Scholar]
  • 107.Vaughan RA. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol Pharmacol. 1995;47:956–964. [PubMed] [Google Scholar]
  • 108.Vaughan RA, Kuhar MJ. Dopamine transporter ligand binding domains: structural and functional properties revealed by limited proteolysis. J Biol Chem. 1996;271:21672–21680. doi: 10.1074/jbc.271.35.21672. [DOI] [PubMed] [Google Scholar]
  • 109.Vaughan RA, Agoston GE, Lever JR, Newman AH. Differential binding of tropane-based photoaffinity ligands on the dopamine transporter. J Neurosci. 1999;19:630–636. doi: 10.1523/JNEUROSCI.19-02-00630.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Lever JR, Zou MF, Parnas ML, et al. Radioiodinated azide and isothiocyanate derivatives of cocaine for irreversible labeling of dopamine transporters: synthesis and covalent binding studies. Bioconjug Chem. 2005;16:644–649. doi: 10.1021/bc0497214. [DOI] [PubMed] [Google Scholar]
  • 111.Vaughan RA, Parnas ML, Gaffaney JD, et al. Affinity labeling the dopamine transporter ligand binding site. J. Neurosci Methods. 2005;143:33–40. doi: 10.1016/j.jneumeth.2004.09.022. [DOI] [PubMed] [Google Scholar]
  • 112.Wirtz SE, Parnas L, Jackson TV, et al. Identification of an MFZ 2–24 photoaffinity labeling site on the human dopamine transporter. Soc Neurosci Abstr. 2004;33:53–53. [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES